Investors

Press Releases

Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering

May 13, 2020

Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19

May 06, 2020

Cardiol Therapeutics Announces Study Demonstrating its Proprietary Nanotechnology Targets Fibrous Tissue in the Heart

April 14, 2020

Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure

April 01, 2020

Cardiol Therapeutics Announces Filing of 2019 Year-end Financial Statements and MD&A

March 26, 2020

Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc.

March 18, 2020

Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation

March 05, 2020

Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

January 15, 2020

Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor

December 18, 2019

Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to its Board of Directors

December 03, 2019